The Board of Directors of Gubra today announces that Markus Rohrwild is stepping down as CEO of the company, effective today, November 10, 2026. The Board has appointed Kristian Borbos, Chief Financial Officer, and Zoë Johnson, Head of Gubra Ventures & Business Development, as Co-CEOs, in addition to their current roles.
Chair of the Board, Monika Lessl, said:
“After careful consideration, the Board has concluded that a change in executive leadership is needed as Gubra continues to implement its 2030 strategy. The Board is confident that Kristian and Zoë bring the right combination of competencies and experience to build on Gubra’s progress and execute its strategy, while preserving the company’s unique culture and values.
On behalf of the Board, I would like to thank Markus for his leadership and contributions to Gubra. We wish him all the best for the future.”
Gubra’s 2030 strategy is unchanged
Gubra’s 2030 strategy, presented on October 27, 2026, remains unchanged. Building on its strong foundation and core strengths, the company aims to scale its innovation engine and expand its portfolio of clinical-stage assets across proprietary, partnered, and venture programs. Disciplined capital allocation will underpin these ambitions, with clear strategic and financial criteria guiding investment decisions across Biotech, CRO, and Ventures.
About the incoming Co-CEOs
Kristian Borbos joined Gubra as Chief Financial Officer (CFO) in 2022. He brings more than 25 years of experience in finance and capital markets, including his previous role as CFO of Ascelia Pharma. Earlier in his career, Kristian held finance and investor relations positions at Novozymes, Ørsted (formerly DONG Energy), and Danske Bank.
Kristian holds an M.Sc. in Finance from Lund University, Sweden.
Zoë Johnson joined Gubra in 2026 as Head of Gubra Ventures & Business Development. She brings more than 25 years of international experience in pharmaceutical R&D, biotechnology, and venture creation. Previously, she served as Chief Scientific and Development Officer at Molecule to Medicine and held Chief Scientific Officer positions at Affivant (a Roivant company) and iOnctura, as well as senior R&D roles at UCB, Merck Serono, and NovImmune.
Zoë holds a Ph.D. in Pharmacology from King's College London, UK.
Contact at Gubra
Investors and Media: Adam Lange (adl@gubra.dk, +45 6646 1589)
About Gubra
Gubra is a clinical-stage bioscience company founded in Denmark in 2008 and listed on Nasdaq Copenhagen. Building on deep expertise in peptide science, translational research, and advanced preclinical models, Gubra combines its AI-driven, disease-agnostic peptide drug discovery platform, streaMLine™, with specialized preclinical research capabilities. The company’s activities are organized into three distinct yet complementary business units: Gubra Biotech, the value driver, focused on discovering and advancing differentiated therapeutics; Gubra CRO, the value enabler, providing specialized preclinical research services; and Gubra Ventures, the value accelerator, focused on advancing selected external innovation through asset-centric ventures that leverage Gubra’s scientific capabilities and shared infrastructure. Gubra has approximately 300 employees and reported revenue of DKK 2.6 billion (USD ~400 million) in 2025.
For more information, visit www.gubra.dk.
Legal Notices
© 2026 Gubra A/S (“Gubra”). All Gubra logos, trademarks and trade names are the property of Gubra A/S or its affiliates. Any third-party trademarks or tradenames referenced are the property of their respective owners and references do not imply third party endorsement or sponsorship. All rights reserved.
This information is intended solely for corporate communications and investor relations purposes. It does not constitute medical advice, advertising, promotion, or marketing of any product. At date of publication, Gubra’s biotechnology or partnered products are investigational development candidates and have not received a marketing authorization in any country worldwide.
This information is not a prospectus or offering circular and does not constitute investment advice or an offer to buy or sell securities in Denmark or any jurisdiction, including the United States.
The information or opinions provided are made at the date of publication and are subject to change. While reasonable care has been taken, Gubra makes no warranty of accuracy, completeness, or reliability. Information or opinions provided may also include third party data that has not been independently verified.
This document may contain forward‑looking statements involving opportunities, expectations, risks and uncertainties, however actual results may differ materially. The forward-looking statements can be identified by words such as “aim”, “anticipate”, “believe” “could”, “estimate”, “expect”, “forecast” “goal”, “intend”, “may”, “plan”, “possible”, “potential”, “would”, and other words and terms of similar meaning. Investors are cautioned not to rely on these statements and Gubra disclaims and excludes all liability caused by such reliance. We do not undertake or commit to update these statements for subsequent changes, unless required by applicable laws, rules or regulation.